4 results match your criteria: "University of Rochestergrid.16416.34[Affiliation]"
Antimicrob Agents Chemother
September 2022
Division of Healthcare Quality Promotion, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Microbiol Spectr
June 2022
Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.
Influenza A viruses (IAV) remain emerging threats to human public health. Live-attenuated influenza vaccines (LAIV) are one of the most effective prophylactic options to prevent disease caused by influenza infections. However, licensed LAIV remain restricted for use in 2- to 49-year-old healthy and nonpregnant people.
View Article and Find Full Text PDFmSystems
April 2022
Genomic Medicine Group, J. Craig Venter Institutegrid.469946.0, La Jolla, California, USA.
Streptococcus mutans promotes a tooth-damaging dysbiosis in the oral microbiota because it can form biofilms and survive acid stress better than most of its ecological competitors, which are typically health associated. Many of these commensals produce hydrogen peroxide; therefore, S. mutans must manage both oxidative stress and acid stress with coordinated and complex physiological responses.
View Article and Find Full Text PDFmBio
August 2021
Department of Medicine, Division of Nephrology, University of Rochestergrid.16416.34 Medical Center, Rochester, New York, USA.
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart.
View Article and Find Full Text PDF